When one patient’s cancer turned out to be two cancers in one — everything changed.
In this powerful episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, shares the story of Fran, a patient diagnosed with Stage IIIC ovarian cancer that revealed two mixed tumor types — low-grade serous and endometrioid carcinoma. After surgery and rising CA-125 levels, standard protocols called for more high-dose chemo, but Fran chose a smarter, more personalized path.
Dr. Prato walks through how his team used deep multi-omics testing (DNA, RNA, and spatial biology) to uncover multiple tumor drivers, hormone resistances, and immune barriers. By combining genetically targeted fractionated chemotherapy (GTF), adjuvant IV phytotherapeutics, and immune cell therapies built in-house, Envita was able to eliminate the cancer, restore energy, and achieve remission — all while strengthening the immune system.
🎯 What You’ll Learn in This Episode:

• How mixed-histology ovarian cancers behave differently from single-type tumors

• Why stromal barriers make traditional IV chemo less effective

• How microdosed, genetically targeted chemo activates immune killing

• The role of DNA, RNA, and immune profiling in mapping resistant pathways

• How phytotherapeutics (like curcumin and resveratrol) support immune repair

• Why precision monitoring of CA-125, methylation, and vesicle scores predicts outcomes
📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: https://www.envita.com
📞 Speak to a care coordinator: 866-830-4576
Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493